1. Radient Pharmaceuticals (RPC)
Company Profile: Radient Pharmaceuticals produces and sells diagnostic tests to monitor and detect types of cancer. Last month, TheStreet's Adam Feuerstein reported that Radient missed a loan payment of $843,750 in May, putting the company in default.Altman Z-score: -629.33 Current Share Price: 20 cents (June 7) 2011 Return: -80% Current Ratio: 0.01, indicating that Radient would have major difficulties covering its short-term liabilities with its current assets. >>To see these stocks in action, visit the Stocks Under $5 at Risk of Bankruptcy portfolio on Stockpickr. -- Written by Robert Holmes in Boston.
>To contact the writer of this article, click here: Robert Holmes. >To follow Robert Holmes on Twitter, go to http://twitter.com/RobTheStreet. >To submit a news tip, send an email to: email@example.com.